Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study

Abstract Background The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yi‐Hsin Liang, Kuo‐Hsing Chen, Yu‐Yun Shao
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2023-07-01
Schriftenreihe:	Cancer Medicine
Schlagworte:	bevacizumab cetuximab EGFR metastatic colorectal cancer panitumumab secondary surgery
Online-Zugang:	https://doi.org/10.1002/cam4.6196
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!